PCAC July 2026: What the 7-Peptide FDA Review Means for Women
The FDA’s Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to review seven peptides for potential compounding eligibility. For women, this meeting matters because several of the peptides under review are directly relevant to conditions that disproportionately affect women — and one of them (BPC-157) has the only published human data specifically in a women’s health condition.
The 7 Peptides and Why Women Should Pay Attention
| Peptide | Day | Women’s Health Relevance |
|---|---|---|
| BPC-157 | July 23 | Interstitial cystitis pilot study (10/12 women responded). Gut healing for women with IBS (2-3x more common in women). Post-surgical recovery. |
| KPV | July 23 | Anti-inflammatory for gut conditions, autoimmune support. Women have higher autoimmune disease rates. |
| TB-500 | July 23 | Tissue repair for post-surgical recovery, joint health (relevant to estrogen-decline joint pain). |
| MOTS-C | July 23 | Insulin sensitization for PCOS. Metabolic support during perimenopause. Exercise-mimetic for fatigue. |
| DSIP | July 24 | Sleep architecture support. Women experience higher rates of insomnia, especially during perimenopause. |
| Semax | July 24 | BDNF upregulation for perimenopausal brain fog. Neuroprotection. |
| Epitalon | July 24 | Telomerase activation for longevity. Melatonin production (sleep support). |
BPC-157: The Strongest Case With Women’s Data
BPC-157 has a unique advantage going into the PCAC meeting: the interstitial cystitis pilot study is one of the few published human datasets for any peptide on the agenda, and it was conducted exclusively in women. The 80-100% symptom resolution in 10 of 12 female participants is the kind of clinical signal the committee looks for.
If BPC-157 receives a positive recommendation, it would become available through compounding pharmacies with a prescription — potentially making it more accessible to women with IC, IBS, and post-surgical recovery needs who prefer the pharmaceutical pathway over research peptides.
How to Submit Public Comment
If you have benefited from any of these peptides through a physician-supervised protocol, your experience is relevant input. Public comments can be submitted through regulations.gov under Docket No. FDA-2025-N-6895. Comments received by July 9, 2026 will be provided to the committee in advance.
BioPure Peptides
Code: POWERAll 7 peptides under review available now as research compounds. Third-party tested.
Shop BioPure →Frequently Asked Questions
Related Articles
Find Your Peptide Match
Take our 60-second quiz for personalized peptide recommendations based on your goals and life stage.
Take the Quiz →